Tyra Biosciences (NASDAQ:TYRA) Reaches New 12-Month High – What’s Next?

Tyra Biosciences, Inc. (NASDAQ:TYRA)’s stock price reached a new 52-week high on Wednesday . The company traded as high as $26.35 and last traded at $26.2750, with a volume of 125611 shares. The stock had previously closed at $25.44.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on TYRA. Wall Street Zen cut shares of Tyra Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday. Raymond James Financial began coverage on Tyra Biosciences in a research report on Tuesday, September 2nd. They set a “strong-buy” rating and a $35.00 target price on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Tyra Biosciences in a research report on Wednesday, October 8th. Oppenheimer restated an “outperform” rating and set a $36.00 price objective on shares of Tyra Biosciences in a research note on Wednesday, September 10th. Finally, Wedbush lifted their target price on Tyra Biosciences from $30.00 to $37.00 and gave the company an “outperform” rating in a research note on Tuesday, December 16th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Tyra Biosciences currently has a consensus rating of “Moderate Buy” and an average price target of $33.17.

Tyra Biosciences Stock Up 2.7%

The firm has a market cap of $1.39 billion, a PE ratio of -13.97 and a beta of 1.09. The stock has a 50 day moving average price of $19.72 and a two-hundred day moving average price of $14.47.

Tyra Biosciences (NASDAQ:TYRA) last released its earnings results on Wednesday, November 5th. The company reported ($0.50) EPS for the quarter, hitting analysts’ consensus estimates of ($0.50). As a group, equities analysts anticipate that Tyra Biosciences, Inc. will post -1.57 earnings per share for the current year.

Insider Transactions at Tyra Biosciences

In other Tyra Biosciences news, Director Robert J. More sold 246,871 shares of Tyra Biosciences stock in a transaction dated Friday, November 21st. The stock was sold at an average price of $20.25, for a total transaction of $4,999,137.75. Following the completion of the sale, the director owned 3,833,425 shares of the company’s stock, valued at approximately $77,626,856.25. The trade was a 6.05% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 15.20% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. HighVista Strategies LLC lifted its holdings in shares of Tyra Biosciences by 4.3% during the second quarter. HighVista Strategies LLC now owns 24,962 shares of the company’s stock worth $239,000 after purchasing an additional 1,021 shares during the period. American Century Companies Inc. lifted its stake in Tyra Biosciences by 5.8% during the 1st quarter. American Century Companies Inc. now owns 23,431 shares of the company’s stock valued at $218,000 after acquiring an additional 1,289 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Tyra Biosciences by 14.5% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 13,182 shares of the company’s stock valued at $126,000 after acquiring an additional 1,668 shares during the period. Federated Hermes Inc. boosted its holdings in shares of Tyra Biosciences by 586.3% in the 3rd quarter. Federated Hermes Inc. now owns 2,155 shares of the company’s stock valued at $30,000 after acquiring an additional 1,841 shares during the last quarter. Finally, Rhumbline Advisers increased its stake in shares of Tyra Biosciences by 7.2% in the first quarter. Rhumbline Advisers now owns 28,081 shares of the company’s stock worth $261,000 after acquiring an additional 1,879 shares during the period. 84.14% of the stock is currently owned by hedge funds and other institutional investors.

Tyra Biosciences Company Profile

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.